Literature DB >> 12745858

A case of recurrent acute generalized exanthematous pustulosis due to beta-lactam antibiotics: a case report.

V Mysore1, A Ghuloom.   

Abstract

A case of acute generalized exanthematous pustulosis (AGEP) is presented. The case is notable for the recurrent episodes of AGEP, caused by three beta-lactam antibiotics (piperacillin, ceftazidime, and meropenem) in septicemic patient. The case represents the first report of the reaction developing in response to these three antibiotics. The report is also notable for the spontaneous resolution of the rash in all the three episodes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745858     DOI: 10.1080/09546630305544

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  5 in total

1.  Acute generalised exanthematous pustulosis (AGEP) after cefotaxime use.

Authors:  Amel Chaabane; Karim Aouam; Khaled Harrathi; Najib Ben Yahia; Elyes Gassab; Leila Njim; Naceur A Boughattas
Journal:  BMJ Case Rep       Date:  2009-05-25

2.  Acute generalized exanthematous pustulosis: an unusual side effect of meropenem.

Authors:  Mohammed Hanafy Khalel; Salhamooud Abdel Fattah Saleh; Abdel-Hamid F El-Gamal; Nabeel Najem
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

3.  Acute generalized exanthematous pustulosis due to meropenem: An unusual side effect of a commonly used drug.

Authors:  Loknath Ghoshal; Saumen Nandi; Aritra Sarkar; Sudip Das
Journal:  Indian Dermatol Online J       Date:  2015 Nov-Dec

4.  Five-Year Retrospective Review of Acute Generalized Exanthematous Pustulosis.

Authors:  Chitprapassorn Thienvibul; Vasanop Vachiramon; Kumutnart Chanprapaph
Journal:  Dermatol Res Pract       Date:  2015-12-10

5.  Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.

Authors:  Ali Nili; Ehsan Zarei; Azin Ghamari; Ali Salehi Farid; Soheil Tavakolpour; Maryam Daneshpazhooh; Hamidreza Mahmoudi
Journal:  Int Immunopharmacol       Date:  2020-10-19       Impact factor: 4.932

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.